19 Sep Considering the Benefits of Music: Not All Alzheimer’s Treatments are Pills or Shots

Sarah Thompson, ACRP

In recognition of September being World Alzheimer’s Month (a campaign of Alzheimer’s Disease International), ACRP sought out commentary on a type of therapy for the disease that’s not as well known to the public as the recently approved pharmaceuticals lacanemab (Leqembi® from Eisai Inc. and Biogen) or donanemab (Kisunla™ from Eli Lilly), or the much older mematine (now marketed under many brand names worldwide). 

Sharing her expertise on how music therapy may be of help in cases of dementia is Sarah Thompson, PhD, MM, currently Executive Director of the Sound Health Network at the University of California, San Francisco (UCSF), which involves leading a music and health initiative for the National Endowment for the Arts with UCSF, the National Institutes of Health (NIH), the Renee Fleming Foundation, and the Kennedy Center. She has also conducted medical device research as a principal investigator (PI) at the University of Colorado Anschutz Medical Campus and Craig Hospital, studied user experience and product research challenges for Clinical Rhythms, and served as CEO and Chair of the Board at the nonprofit Rehabilitative Rhythms, among other accomplishments. Read more…